SCHEMBL146149

SCHEMBL146149

N#Cc1ccc(N2CCCC(NC(=O)OCc3ccccc3)C2)c2c1[nH]c1cc(C(=O)O)ccc12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSK P43235 1/20 0.46
BTK Q06187 9/20 0.46
SMPD3 Q9NY59 1/20 0.38
EPHX1 P07099 1/20 0.37
PREP P48147 2/20 0.37
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
HSD11B1 P28845 1/20 0.36
ENPP2 Q13822 1/20 0.36
ATXN2 Q99700 1/20 0.36
DPP4 P27487 2/20 0.36
DPP7 Q9UHL4 2/20 0.36
KCNH2 Q12809 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL146148 1.00 CTSL (0.46) CTSLCTSBCTSKBTKSMPD3
SCHEMBL17707883 0.83 BTK (0.53) CTSLCTSBCTSKBTK
SCHEMBL20853431 0.83 BTK (0.53) CTSLCTSBCTSKBTK
SCHEMBL29782624 0.83 BTK (0.53) CTSLCTSBCTSKBTK
SCHEMBL151127 0.82 BTK (0.44) BTKGAADPP4
SCHEMBL151126 0.82 BTK (0.44) BTKGAADPP4
SCHEMBL21509090 0.80 BTK (0.55) CTSLCTSBCTSKBTK
SCHEMBL21509051 0.80 CTSL (0.47) CTSLCTSBCTSKBTKSMPD3
SCHEMBL19715369 0.80 CTSL (0.47) CTSLCTSBCTSKBTKSMPD3
SCHEMBL19735752 0.80 BTK (0.55) CTSLCTSBCTSKBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 EP disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
EP-2391602-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-12-07 EP disclosed
WO-2010080481-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 CTSL 2162/4885CTSB 1418/4885CTSK 845/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 CTSL 2162/4885CTSB 1418/4885CTSK 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.